Drug Profile
PF 4325667
Alternative Names: PF-4325667Latest Information Update: 28 Jan 2010
Price :
$50
*
At a glance
- Originator Pfizer
- Class Obesity therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obesity; Type 2 diabetes mellitus
Most Recent Events
- 27 Jan 2010 Discontinued - Phase-I for Obesity in USA (unspecified route)
- 27 Jan 2010 Discontinued - Phase-I for Type-2 diabetes mellitus in USA (unspecified route)
- 30 Sep 2008 Phase-I clinical trials in Type-2 diabetes mellitus in USA (unspecified route)